CapitolRadar tracks every publicly disclosed GILD trade by US congress members and corporate insiders: 27 disclosed trades (16 buys, 11 sells) by 5 tracked traders, from 2021-01-21 to 2026-08-10. Updated daily from official filings.
Want a ping when Congress buys GILD? Free email alerts on notable disclosed trades — plus a $100,000 fantasy portfolio to play along against three AI traders. Join free
Gilead Sciences, Inc. (GILD) — Healthcare · Drug Manufacturers - General, market cap about $195.1B.
CapitolRadar analysis
26 disclosed trades skewed toward purchases
26 tracked GILD trades comprise 16 buys and 10 sells by five distinct traders from January 21, 2021 through July 7, 2026. Buys therefore account for the larger share of the recorded activity, but the five-trader sample is small and does not establish a broad congressional pattern. Gilead Sciences is classified in Healthcare and the Drug Manufacturers - General industry.
7 buys by Ro Khanna make him the most frequent recorded buyer, with his latest purchase dated March 25, 2024. Marjorie Taylor Greene follows with four buys, most recently on June 6, 2025. Josh Gottheimer and Tommy Tuberville each made two purchases, last dated January 27, 2026 and May 10, 2024, respectively. Jared Moskowitz made one buy, dated May 6, 2026.
4 trades made 2024 Q2 the busiest listed quarter
4 trades in 2024 Q2 included two buys, the highest total among the quarters provided. The next-largest listed period was 2025 Q2, with three trades and two buys. The supplied quarterly data also show two trades with one buy in 2024 Q1, plus one buy in each of 2024 Q4, 2025 Q1, 2026 Q1 and 2026 Q2. The single 2026 Q3 trade was a sell. Because only selected quarters are listed, this quarterly view does not account for all 26 tracked trades.
3 buyers also appeared in PANW
3 of the five GILD buyers also bought PANW. Two buyers apiece also purchased AXP, CB, ADI, HD and FCX. These overlaps describe disclosed trading records only and do not indicate a shared rationale or coordinated activity.
Up to 45 days of disclosure lag can separate a transaction from its public filing, so reported activity may not be current when published. Disclosed transaction amounts are reported as ranges, making any dollar totals estimates rather than exact values. The limited number of traders and trades also warrants caution when interpreting concentration or timing.
Analysis written from the tracked record on 2026-09-09; it is refreshed whenever the underlying numbers change.
Activity by quarter
| Quarter | Disclosed trades | Buys | Sells |
|---|---|---|---|
| 2026 Q3 | 2 | 0 | 2 |
| 2026 Q2 | 1 | 1 | 0 |
| 2026 Q1 | 1 | 1 | 0 |
| 2025 Q2 | 3 | 2 | 1 |
| 2025 Q1 | 1 | 1 | 0 |
| 2024 Q4 | 1 | 1 | 0 |
| 2024 Q2 | 4 | 2 | 2 |
| 2024 Q1 | 2 | 1 | 1 |
Who is buying GILD?
| Trader | Disclosed buys | Last buy | Grade |
|---|---|---|---|
| Ro Khanna | 7 | 2024-03-25 | — |
| Marjorie Taylor Greene | 4 | 2025-06-06 | — |
| Josh Gottheimer | 2 | 2026-01-27 | — |
| Tommy Tuberville | 2 | 2024-05-10 | — |
| Jared Moskowitz | 1 | 2026-05-06 | — |
Disclosed trades in GILD
| Date | Who | Type | Amount | 30d vs SPY |
|---|---|---|---|---|
| 2026-08-10 | Ro Khanna | sell | $1,001 - $15,000 | — |
| 2026-07-07 | Ro Khanna | sell | $1,001 - $15,000 | — |
| 2026-05-06 | Jared Moskowitz | buy | $1,001 - $15,000 | — |
| 2026-01-27 | Josh Gottheimer | buy | $1,001 - $15,000 | — |
| 2025-06-06 | Marjorie Taylor Greene | buy | $1,001 - $15,000 | — |
| 2025-05-14 | Josh Gottheimer | sell | $1,001 - $15,000 | — |
| 2025-05-05 | Marjorie Taylor Greene | buy | $1,001 - $15,000 | — |
| 2025-03-07 | Josh Gottheimer | buy | $1,001 - $15,000 | — |
| 2024-12-24 | Marjorie Taylor Greene | buy | $1,001 - $15,000 | — |
| 2024-05-10 | Tommy Tuberville | buy | $1,001 - $15,000 | — |
| 2024-05-08 | Tommy Tuberville | sell | $1,001 - $15,000 | — |
| 2024-04-05 | Tommy Tuberville | buy | $1,001 - $15,000 | — |
| 2024-04-03 | Tommy Tuberville | sell | $1,001 - $15,000 | — |
| 2024-03-25 | Ro Khanna | buy | $1,001 - $15,000 | — |
| 2024-02-13 | Ro Khanna | sell | $1,001 - $15,000 | — |
| 2023-11-03 | Ro Khanna | buy | $1,001 - $15,000 | — |
| 2023-10-02 | Ro Khanna | sell | $1,001 - $15,000 | — |
| 2022-09-29 | Ro Khanna | buy | $1,001 - $15,000 | — |
| 2022-09-06 | Ro Khanna | buy | $1,001 - $15,000 | — |
| 2022-08-01 | Ro Khanna | sell | $1,001 - $15,000 | — |
These buyers also bought
Other stocks the tracked buyers of GILD disclosed buying in the last six months: MSFT (3) · HD (2) · GOOGL (2) · SNDK (2) · RSG (2) · MNST (2).
About Gilead Sciences, Inc.
Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In response to the 2019 coronavirus pandemic, Gilead provides Veklury, an injectabl…
Frequently asked questions
Which politicians bought GILD most?
Ro Khanna leads with 7 disclosed buys, followed by Marjorie Taylor Greene.
How current is this page?
It re-renders from the tracked record on every view and new filings are ingested daily — but STOCK Act disclosures can lag the trade by up to 45 days, so the most recent weeks are always incomplete.
Get alerts when trades like these are disclosed. Free account: fantasy portfolio + email alerts. Premium: a 6-hour head start on every signal.
CapitolRadar tracks publicly disclosed trades (STOCK Act filings and SEC Form 4). Disclosures can lag the trade by up to 45 days. Backtests measure past disclosed buys against the S&P 500 and do not predict future results. Everything on this page is impersonal information for your own research — not investment advice.